| 1 |
Novartis Pharmaceuticals Corporation et al v. Cipla Limited et al |
1:25-cv-00216 |
D.Del. |
|
|
|
|
| 2 |
Novartis Pharmaceuticals Corporation et al v. Cipla Limited et al |
1:25-cv-00216 |
D.Del. |
|
|
|
|
| 3 |
AMERICAN REGENT, INC. v. CIPLA USA, INC. et al |
2:24-cv-11112 |
D.N.J. |
|
|
|
|
| 4 |
SALIX PHARMACEUTICALS, INC. et al v. CIPLA USA, INC. et al |
1:24-cv-10213 |
D.N.J. |
|
|
|
|
| 5 |
SALIX PHARMACEUTICALS, INC. et al v. CIPLA USA, INC. et al |
1:24-cv-10213 |
D.N.J. |
|
|
|
|
| 6 |
SALIX PHARMACEUTICALS, INC. et al v. CIPLA USA, INC. et al |
1:24-cv-10213 |
D.N.J. |
|
|
|
|
| 7 |
SALIX PHARMACEUTICALS, INC. et al v. CIPLA USA, INC. et al |
1:24-cv-10213 |
D.N.J. |
|
|
|
|
| 8 |
AMERICAN REGENT, INC. v. CIPLA USA, INC. et al |
2:24-cv-07796 |
D.N.J. |
|
|
|
|
| 9 |
JAZZ PHARMACEUTICALS RESEARCH UK LIMITED v. APOTEX INC. et al |
2:24-cv-07550 |
D.N.J. |
|
|
|
|
| 10 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 11 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 12 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 13 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 14 |
THERAVANCE BIOPHARMA R&D IP, LLC et al v. EUGIA PHARMA SPECIALTIES LTD. et al |
1:23-cv-00926 |
D.N.J. |
|
- 8 Product company
- 12 IP subsidiary of product company
|
|
|
| 15 |
GW RESEARCH LIMITED v. TEVA PHARMACEUTICALS, INC. et al |
2:23-cv-00018 |
D.N.J. |
|
|
|
|
| 16 |
PAR PHARMACEUTICAL, INC. et al v. CIPLA LIMITED et al |
2:22-cv-02814 |
D.N.J. |
|
|
|
|
| 17 |
PAR PHARMACEUTICAL, INC. et al v. CIPLA LIMITED et al |
2:22-cv-02814 |
D.N.J. |
|
|
|
|
| 18 |
PAR PHARMACEUTICAL, INC. et al v. CIPLA LIMITED et al |
2:22-cv-02814 |
D.N.J. |
|
|
|
|
| 19 |
Genzyme Corp. et al v. Cipla Limited |
1:18-cv-01838 |
D.Del. |
|
- 8 Product company
- 6 University/Government/Non-profit
|
|
|
| 20 |
Genzyme Corp. et al v. Cipla Limited |
1:18-cv-01838 |
D.Del. |
|
- 8 Product company
- 6 University/Government/Non-profit
|
|
|
| 21 |
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mankind Pharma Ltd. et al |
1:18-cv-01689 |
D.Del. |
|
|
|
|
| 22 |
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mankind Pharma Ltd. et al |
1:18-cv-01689 |
D.Del. |
|
|
|
|
| 23 |
Boehringer Ingelheim Pharmaceuticals Inc. et al v. Mankind Pharma Ltd. et al |
1:18-cv-01689 |
D.Del. |
|
|
|
|
| 24 |
Anacor Pharmaceuticals, Inc. v. Ascent Pharmaceuticals, Inc. et al |
1:18-cv-01673 |
D.Del. |
|
|
|
|
| 25 |
CELGENE CORPORATION v. CIPLA LIMITED |
3:18-cv-11262 |
D.N.J. |
|
|
|
|